Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Tamorah R Lewis Md PhD"'
Autor:
Norma Terrin, Tamorah R Lewis Md PhD, Jonathan M. Davis, Thomas Salaets, Kurt Michels, Kelly C. Wade
Publikováno v:
Journal of Perinatology
Objective The Neonatal Adverse Event Severity Scale (NAESS) was developed to improve scoring of neonatal adverse events (AEs) and accelerate neonatal drug development. This is the first validation study of the novel tool. Study design Retrospective v
Publikováno v:
NeoReviews. 21:e454-e468
Few medications are available and well tested to treat infants who already have developed or inevitably will develop severe bronchopulmonary dysplasia (sBPD). Infants who develop sBPD clearly have not benefited from decades of research efforts to ide
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 14
Autor:
Tamorah R Lewis Md PhD, Sydney R Rooney, Prince J. Kannankeril, Elaine L. Shelton, Christian M. Shaffer, Sara L. Van Driest, Jeff Reese, John M. Dagle, Ida Aka, Ronald I. Clyman, Kelli K. Ryckman
Publikováno v:
Pharmacogenomics
Pharmacogenomics, vol 20, iss 13
Pharmacogenomics, vol 20, iss 13
Aims: To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). Patients & Methods: This is a multicenter cohort study of 144 preterm infants (22–32 weeks gestati
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 12, Iss 6, Pp 591-599 (2019)
Clinical and Translational Science, Vol 12, Iss 6, Pp 591-599 (2019)
A prospective cohort study was performed in preterm infants less than 32 weeks gestation at birth who were treated with dexamethasone for developing or established bronchopulmonary dysplasia (BPD). Respiratory phenotype (Respiratory Severity Score (R
Autor:
Jogarao V. S. Gobburu, Tao Liu, Walter K. Kraft, Vijay Ivaturi, Estelle B. Gauda, David E. Moody, Jason N. Moore, Tamorah R Lewis Md PhD, David Alan Sartori
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 7, Pp 469-477 (2019)
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 7, Pp 469-477 (2019)
Neonates experience dramatic changes in the disposition of drugs after birth as a result of enzyme maturation and environmental adjustment, challenging therapeutic decision making. In this research, we establish postnatal age, postmenstrual age, and
Autor:
Joseph M. Collaco, Anarina L. Murillo, Sherry E. Courtney, Steven H. Abman, Martin Keszler, Khanh Lai, William E Truog, Kristen T. Leeman, Kathleen E. Hannan, Michael C. Tracy, Christopher D. Baker, Jonathan J Levin, Lauren A Sanlorenzo, Laurie C. Eldredge, Matthew J. Kielt, Amit Agarwal, Natalie Napolitano, David N. Matlock, Rebecca Rose, Matthew Douglass, Tamorah R Lewis Md PhD, Milenka Cuevas Guaman, Sharon A. McGrath-Morrow, Bpd Collaborative, Robin L. McKinney, Richard Sindelar
Publikováno v:
The Journal of Pediatrics. 242:248-252.e1
We performed a point prevalence study on infants with severe BPD collecting data on type and settings of ventilatory support; 187 infants were included from 15 centers, 51% who were on invasive positive pressure ventilation. We found significant cent
Publikováno v:
BMC Pediatrics, Vol 18, Iss 1, Pp 1-6 (2018)
BMC Pediatrics
BMC Pediatrics
Background Although neonates and young infants with cholestasis are commonly treated with either phenobarbital or ursodeoxycholic acid (ursodiol), there is no evidence that phenobarbital is effective for this indication. Our objective was to compare
Publikováno v:
Current Treatment Options in Pediatrics. 4:108-118
With heightened awareness of long-term neurocognitive effects of pain and stress in the neonatal population, increased focus has been placed on pain assessment as well as potential effects of routinely administered analgesics/sedatives in our neonata
Autor:
Anne Ball, Eugenia K. Pallotto, Tamorah R Lewis Md PhD, Bridget Blowey, Kelly Tracy, Alexandra Oschman, Kimberly J. Reid
Publikováno v:
Journal of Neonatal Nursing. 23:223-227
Objectives To evaluate the impact of targeting 2 mg/kg/day of enteral iron supplementation versus 4 mg/kg/day on hemoglobin and transfusion endpoints in very low birth weight neonates. Methods Retrospective cohort study of neonates less than 32 weeks